Can Targeting Glutaminolysis be a Therapeutic Strategy?
Given its critical role in cancer metabolism, targeting glutaminolysis presents a promising therapeutic strategy. Inhibitors of glutaminase, the enzyme that catalyzes the first step of glutaminolysis, have shown potential in preclinical studies. Drugs like CB-839 are being tested in clinical trials to evaluate their efficacy against various cancers. Combining glutaminolysis inhibitors with other treatments, such as chemotherapy or immune checkpoint inhibitors, may enhance therapeutic outcomes.
